Literature DB >> 10487653

An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species.

A Vos1, A Neubert, O Aylan, P Schuster, E Pommerening, T Müller, D C Chivatsi.   

Abstract

SAD B19 is an attenuated vaccine virus for oral vaccination of carnivores against rabies. The safety of SAD B19 was investigated in 16 animal species by different routes of administration. During the observation period all animals given the vaccine virus, irrespective of the route of administration, did not show any clinical signs of rabies, with the exception of certain rodent species. In these animals a low residual pathogenicity was observed, however transmission of the vaccine virus to control animals was not demonstrable. No vaccine virus could be detected in the saliva of the six mammal species examined. Furthermore, the genetical stability was shown for SAD B19 through passaging in neural tissue of dogs, foxes and mice. From the results presented here on innocuity and stability, it can be concluded that SAD B19 rabies vaccine is suitable for oral vaccination campaigns for carnivores against rabies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487653      PMCID: PMC2810740          DOI: 10.1017/s0950268899002666

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  22 in total

1.  Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

Authors:  Renata da Fontoura Budaszewski; Andrew Hudacek; Bevan Sawatsky; Beate Krämer; Xiangping Yin; Matthias J Schnell; Veronika von Messling
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Recombinant rabies virus vaccine strain SAD-l16 inoculated intracerebrally in young mice produces a severe encephalitis with extensive neuronal apoptosis.

Authors:  Pamini Rasalingam; John P Rossiter; Alan C Jackson
Journal:  Can J Vet Res       Date:  2005-04       Impact factor: 1.310

3.  Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.

Authors:  Joseph E Blaney; Christoph Wirblich; Amy B Papaneri; Reed F Johnson; Carey J Myers; Terry L Juelich; Michael R Holbrook; Alexander N Freiberg; John G Bernbaum; Peter B Jahrling; Jason Paragas; Matthias J Schnell
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

4.  Rhabdovirus-based vaccine platforms against henipaviruses.

Authors:  Drishya Kurup; Christoph Wirblich; Heinz Feldmann; Andrea Marzi; Matthias J Schnell
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

5.  A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.

Authors:  Amy B Papaneri; Christoph Wirblich; Jennifer A Cann; Kurt Cooper; Peter B Jahrling; Matthias J Schnell; Joseph E Blaney
Journal:  Virology       Date:  2012-08-11       Impact factor: 3.616

Review 6.  Transneuronal circuit tracing with neurotropic viruses.

Authors:  Edward M Callaway
Journal:  Curr Opin Neurobiol       Date:  2009-04-06       Impact factor: 6.627

7.  Field trial with oral vaccination of dogs against rabies in the Philippines.

Authors:  R Estrada; A Vos; R De Leon; T Mueller
Journal:  BMC Infect Dis       Date:  2001-11-28       Impact factor: 3.090

8.  Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Authors:  Joseph E Blaney; Andrea Marzi; Mallory Willet; Amy B Papaneri; Christoph Wirblich; Friederike Feldmann; Michael Holbrook; Peter Jahrling; Heinz Feldmann; Matthias J Schnell
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

9.  Development in Immunoprophylaxis against Rabies for Animals and Humans.

Authors:  Sukdeb Nandi; Manoj Kumar
Journal:  Avicenna J Med Biotechnol       Date:  2010-01

10.  Spatio-temporal Use of Oral Rabies Vaccines in Fox Rabies Elimination Programmes in Europe.

Authors:  Thomas F Müller; Ronald Schröder; Patrick Wysocki; Thomas C Mettenleiter; Conrad M Freuling
Journal:  PLoS Negl Trop Dis       Date:  2015-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.